InMed Rockets with INM-901 as Potential Alzheimer's Game-Changer
- October 24th, 2023
- 844 views
Shares of InMed Pharmaceuticals Inc. (Nasdaq: INM) surged by over 100% in pre-market trading following the company's announcement that it has identified a promising lead candidate, INM-901, for the treatment of Alzheimer's disease, based on highly positive proof-of-concept study results.
InMed said that its cannabinoid analog INM-901 showed early potential in targeting various Alzheimer's-related pathways, including brain neuron protection and improved neuronal function. Preclinical studies also indicated positive trends in cognitive function, locomotor activity, anxiety-based behavior, and sound awareness compared to a placebo group.
The cannabinoid-focused drugmaker is now gearing up for advanced preclinical studies, including drug metabolism and pharmacokinetics, and taking steps toward pharmaceutical drug development.
$INM was trading a $1.58 in pre-market, up $1.00 (+172.41%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login